Bionano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes. Its Saphyr system includes an instrument, chip consumables, reagents, a suite of data analysis tools, and genome analysis services for researchers to evaluate optical genome mapping data. The company's Bionano prep kits and labeling kits provide the reagents and protocols needed to extract and label ultra-high molecular weight DNA for use with the Saphyr system; and data solutions offering includes a suite of hardware and software for end-to-end experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing. It sells its products for research use applications primarily to laboratories associated with academic and governmental research institutions, as well as to pharmaceutical, biotechnology, and contract research companies in the United States and Canada, Europe, the Middle East, India, Africa, China, Japan, South Korea, Singapore, and Australia. Bionano Genomics, Inc. has a procurement and collaboration agreement with NuProbe, Inc. for research and product development in the fields of reproductive health and oncology liquid biopsies. The company was formerly known as BioNano Genomics, Inc. and changed its name to Bionano Genomics, Inc. in July 2018. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
IPO Year: 2018
Exchange: NASDAQ
Website: bionanogenomics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/15/2024 | Buy → Neutral | Ladenburg Thalmann | |
| 9/10/2024 | Buy → Neutral | BTIG Research | |
| 1/5/2023 | $4.00 | Sector Outperform | Scotiabank |
| 12/12/2022 | $3.50 | Buy | BTIG Research |
| 7/18/2022 | $12.00 | Outperform | Oppenheimer |
8-K/A - Bionano Genomics, Inc. (0001411690) (Filer)
8-K - Bionano Genomics, Inc. (0001411690) (Filer)
10-Q - Bionano Genomics, Inc. (0001411690) (Filer)
8-K - Bionano Genomics, Inc. (0001411690) (Filer)
DEFA14A - Bionano Genomics, Inc. (0001411690) (Filer)
DEF 14A - Bionano Genomics, Inc. (0001411690) (Filer)
PRE 14A - Bionano Genomics, Inc. (0001411690) (Filer)
424B5 - Bionano Genomics, Inc. (0001411690) (Filer)
S-8 - Bionano Genomics, Inc. (0001411690) (Filer)
10-K - Bionano Genomics, Inc. (0001411690) (Filer)
Ladenburg Thalmann downgraded Bionano Genomics from Buy to Neutral
BTIG Research downgraded Bionano Genomics from Buy to Neutral
Scotiabank initiated coverage of Bionano Genomics with a rating of Sector Outperform and set a new price target of $4.00
BTIG Research resumed coverage of Bionano Genomics with a rating of Buy and set a new price target of $3.50
Oppenheimer resumed coverage of Bionano Genomics with a rating of Outperform and set a new price target of $12.00
BTIG initiated coverage of Bionano Genomics with a rating of Buy and set a new price target of $10.00
Oppenheimer reiterated coverage of Bionano Genomics with a rating of and set a new price target of $15.00 from $1.50 previously
LADENBURG THALM/SH SH reiterated coverage of Bionano Genomics with a rating of Buy and set a new price target of $14.00 from $1.25 previously
Maxim Group reiterated coverage of Bionano Genomics with a rating of and set a new price target of $14.00 from $2.00 previously
4 - Bionano Genomics, Inc. (0001411690) (Issuer)
4 - Bionano Genomics, Inc. (0001411690) (Issuer)
4 - Bionano Genomics, Inc. (0001411690) (Issuer)
4 - Bionano Genomics, Inc. (0001411690) (Issuer)
4 - Bionano Genomics, Inc. (0001411690) (Issuer)
4 - Bionano Genomics, Inc. (0001411690) (Issuer)
4 - Bionano Genomics, Inc. (0001411690) (Issuer)
4 - Bionano Genomics, Inc. (0001411690) (Issuer)
4 - Bionano Genomics, Inc. (0001411690) (Issuer)
4 - Bionano Genomics, Inc. (0001411690) (Issuer)
SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Wednesday, May 14, 2025, at 4:30 p.m. Eastern Time to report financial results for the first quarter 2025 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Wednesday, May 14th, 2025Time:4:30 p.m. ETParticipant Link:Registration – Click hereWebcast Link:https://edge.media-server.com/mmc/p/vncjmqc9 Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations website at https://ir.b
SAN DIEGO, March 14, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Monday, March 31, 2025, at 4:30 p.m. Eastern Time to report financial results for the fourth quarter and full year 2024 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Monday, March 31st, 2025Time:4:30 p.m. ETParticipant Link:Registration – Click HereWebcast Link:https://edge.media-server.com/mmc/p/5v2s5x5r Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations website
SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Wednesday, November 13, 2024, at 4:30 p.m. Eastern Time to report financial results for the third quarter 2024 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Wednesday, November 13th, 2024Time:4:30 p.m. ETParticipant Link:Registration – Click HereWebcast Link:https://edge.media-server.com/mmc/p/dmabxin9 Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations website at h
SAN DIEGO, July 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Wednesday, August 7, 2024, at 4:30 p.m. Eastern Time to report financial results for the second quarter 2024 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Wednesday, August 7th, 2024Time:4:30 p.m. ETParticipant Link:Registration – Click HereWebcast Link:https://edge.media-server.com/mmc/p/jojadok2/ Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations website at h
SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Wednesday, May 8, 2024, at 4:30 p.m. Eastern Time to report financial results for the first quarter 2024 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Wednesday, May 8th, 2024Time:4:30 p.m. ETParticipant Dial-In:Toll Free: 1-833-630-1956International: 1-412-317-1837Webcast Link:https://edge.media-server.com/mmc/p/5z343pph/ Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor re
Q4 2023 revenue was $10.7 million, which represents a 30% increase over Q4 2022FY 2023 revenue was $36.1 million, which represents a 30% increase over FY 2022Reached installed base of 326 optical genome mapping (OGM) systems as of YE 2023; increase of 36% over the 240 installed systems as of YE 2022Sold 26,444 nanochannel array flowcells in FY 2023, which represents a 72% increase over the flowcells sold in FY 2022Conference call today, March 5, 2024 at 4:30 PM ET SAN DIEGO, March 05, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2023 and revenue outlook for 2024. "2023 was a year in
SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Tuesday, March 5, 2024, at 4:30 p.m. Eastern Time to report financial results for the fourth quarter and year end 2023 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Tuesday, March 5th, 2024Time:4:30 p.m. ETParticipant Call Link:Registration – Click HereWebcast Link:https://edge.media-server.com/mmc/p/afaym86g/ Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations
SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. ("Bionano") (NASDAQ:BNGO) today announced that is has amended the convertible debt financing the company entered into in October 2023 pursuant to which the company agreed to issue and sell to a certain accredited investor (the "Buyer") (i) in a registered offering by the company (a) $45.0 million aggregate principal amount of senior secured convertible notes due 2025 initially convertible by the Buyer into approximately 15.7 million shares of the company's common stock (the "Initial Registered Note"), and (b) warrants to purchase up to 21.7 million shares of the company's common stock, and (ii) in a concurrent private plac
SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Wednesday, November 8, 2023, at 4:30 p.m. Eastern Time to report financial results for the third quarter 2023 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Wednesday, November 8th, 2023Time:4:30 p.m. ETParticipant Call Link:Registration – Click HereWebcast Link:https://edge.media-server.com/mmc/p/xoj2hwr3 Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations website a
SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Wednesday, August 9, 2023, at 4:30 p.m. Eastern Time to report financial results for the second quarter 2023 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Wednesday, August 9th, 2023Time:4:30 p.m. ETParticipant Call Link:Registration – Click HereWebcast Link:https://edge.media-server.com/mmc/p/kdtv69k5 Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations website at h
QUEBEC CITY, Canada, Nov. 15, 2023 (GLOBE NEWSWIRE) -- LeddarTech®, an automotive software company that provides patented disruptive low-level sensor fusion and perception software technology for ADAS and AD, proudly announces the appointment of Mr. Chris Stewart as Chief Financial Officer ("CFO"). As CFO at LeddarTech, Mr. Stewart will be instrumental in supporting LeddarTech in completing its recently announced business combination with Prospector Capital Corp. and transitioning to a publicly traded company. Mr. Stewart has over 20 years of financial management experience at companies ranging from startups to large public companies. Mr. Stewart previously served as the Chief Financial
SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that Gülsen Kama will serve as its next Chief Financial Officer (CFO), effective September 11, 2023. Christopher Stewart, who held the position of CFO since September 2020, will stay on during the transition and then move into an advisory role. Ms. Kama has an extensive background in business planning and execution, especially in operating environments that demand rigorous management of expenses to enable profitable growth. She was most recently Chief Financial Officer at Northern Data AG, where she created and implemented a global finance organization to enable strong growth. Prior to Northe
SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it has appointed Donna Polizio as its global head of market access, further strengthening its leadership team. The appointment of a global head of market access reflects Bionano's focus on advancing the adoption of optical genome mapping (OGM) and working to meet market needs. Ms. Polizio was most recently the vice president of U.S. managed care and reimbursement at Genomic Health, acquired by Exact Sciences in 2019. In this role, she managed payor contracting and reimbursements that helped drive profitability of Genomic Health prior to its acquisition. Ms. Polizio has also held senior l
TwinStrand Biosciences, Inc., the pioneer and developer of duplex sequencing, today announced the appointment of Goran Pljevaljcic, Ph.D. as Chief Commercial Officer. Dr. Pljevaljcic brings a successful track-record of commercial leadership in the genomics industry to TwinStrand, including experience building and managing clinical and research products through all stages of commercialization. "TwinStrand is pleased to welcome Goran to the team. His experience further solidifies our management team and brings capabilities that will be invaluable as we continue to expand our commercial portfolio of high-resolution duplex sequencing offerings," said TwinStrand CEO Jesse Salk, M.D., Ph.D. "Gor
SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™, the leading software solution for visualization, interpretation and reporting of genomic data, today announced the appointment of Aleks Rajkovic, MD, PhD, to its board of directors. Dr. Rajkovic is currently the Chief Genomics Officer at the University of California, San Francisco (UCSF), a Stuart Lindsay Distinguished Professor in Experimental Pathology, and Medical Director and Chief of the Center for Genetic and Genomic Medicine at UCSF Health. Prior to arriving to UCSF, he was the Chief of Medical and L
SAN DIEGO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™, the leading software solution for visualization, interpretation and reporting of genomic data, today announced that it has appointed Helene Klein as its chief people officer, further strengthening its leadership team. As the company expands, culture and employee experience become key success factors. The appointment of a chief people officer today reflects Bionano's focus on maintaining and evolving its culture of innovative, disciplined, and rapid response to market needs. Ms. Klein was formerly the chief people o
SAN DIEGO, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of the leading software solutions for visualization, interpretation and reporting of genomic data, today announced the appointment of Vincent Wong, JD, MBA, to its board of directors. Mr. Wong is currently the chief commercial officer at Geneoscopy, Inc., a life sciences company focused on the development of diagnostic tests for gastrointestinal health. He joined Geneoscopy in March 2021 after almost 18 years at Roche Diagnostics, where he held senior leadership roles across the spectrum of commercial execution, including product
SAN DIEGO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of the leading software for genomic data visualization, interpretation and reporting, today announced that it has appointed Keith Gligorich, PhD, MB(ASCP)cm to the role of VP Operations for Bionano Laboratories. Keith was most recently with Guarant Health where he led the build-out of Guardant's CLIA-certified, CAP-accredited laboratory for blood-based early cancer detection testing. He has over a decade of experience in molecular diagnostic test development and laboratory operations. Prior to joining Guardant Health, Keith held le
SAN DIEGO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), developer of the Saphyr® system that uses optical genome mapping (OGM) for the detection and analysis of structural variants (SVs), today announced that two former Illumina executives, Stephanie Hoyle and Alex Helm, have joined the Company as vice presidents of Corporate Marketing and Strategic Product Marketing, respectively. Together, they bring 22 years of experience in the genomics space and 36 years of experience in marketing. At Bionano, Stephanie will oversee global marketing and brand strategy for the Company. During her tenure at Illumina, she worked in similar positions and was instrumental in developi
SAN DIEGO, June 14, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) announced today that Richard Shippy has joined the company as its Chief Business Officer. Richard was one of the transformational leaders at Affymetrix who brought microarrays into the clinic and paved the way for the first FDA-cleared application of microarrays in cytogenetics with the CytoScan HD Array developed by Affymetrix. For Bionano, he will be responsible for leading product strategy, broadening its business into new markets and strategic expansion of its product and technology portfolios. "We are thrilled to welcome Rich to Bionano. He adds a highly complementary skillset to our team as we put in p
SAN DIEGO, June 18, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics (NASDAQ:BNGO) recently participated in the European Society of Human Genetics (ESHG) conference held in Milan, Italy, from May 24-27, 2025. The event highlighted the use of optical genome mapping (OGM) in genetic disease research, with numerous presentations and posters emphasizing its utility in detecting structural variants (SVs) associated with genetic diseases – including constitutional disorders, hematological malignancies and solid tumors. Key Highlights from ESHG 2025: Scientific Presentations and Posters: A total of 21 studies with authors representing 12 different countries were presented – either or
SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (NASDAQ:BNGO) that offers CLIA-certified laboratory developed tests (LDTs) based on optical genome mapping (OGM), today announced that the editorial panel of the American Medical Association (AMA) established a new Category I Current Procedural Terminology (CPT®) code for the use of OGM in cytogenomic genome-wide analysis to detect structural and copy number variations related to constitutional genetic disorders. The CPT code is a key component in obtaining reimbursement for the OGM-Dx™ Postnatal Whole Genome SV and OGM-Dx™ Prenatal Whole Genome SV LDTs from third party pay
SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today reported financial results for the first quarter ended March 31, 2025. "The first quarter of 2025 represents the first full quarter of execution after shifting strategy towards a focus on our base of routine users of optical genome mapping (OGM) and VIA™ software as the primary drivers of our revenue and gross profit. We are pleased to see consistent utilization of our OGM systems and software combined with a year-over-year growth in consumables purchased by our customers we consider to be routine users of OGM. After significant reductions in costs and cash burn, together with our gross margin improve
In 58% or 303 of 519 cases, optical genome mapping (OGM) revealed somatic aberrations that were not detected by the standard cytogenetic workup (SCGW), including Tier 1, Tier 2 and Tier 3 structural variants (SVs) and copy number variants (CNVs)In 15% or 75 of 519 cases, OGM identified additional Tier 1 variants with detection rates varying by disease type, ranging from 52% in T-ALL to 0% in MPN. Every Tier 1 SV or CNV detected by OGM had direct diagnostic, prognostic, or therapeutic significance, meaning that the detection would provide additional clinical utility SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (NASD
SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Wednesday, May 14, 2025, at 4:30 p.m. Eastern Time to report financial results for the first quarter 2025 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Wednesday, May 14th, 2025Time:4:30 p.m. ETParticipant Link:Registration – Click hereWebcast Link:https://edge.media-server.com/mmc/p/vncjmqc9 Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations website at https://ir.b
SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (NASDAQ:BNGO) that offers CLIA-certified laboratory developed tests (LDTs) based on optical genome mapping (OGM), today announced the publication in the American Journal of Hematology of expert recommendations from the International Consortium for Optical Genome Mapping (ICOGM) for the integration of OGM as a standard-of-care (SOC) cytogenetic assay for diagnostic workflows in various clinical settings. Nineteen (19) experts from the ICOGM, representing relevant multidisciplinary fields, conducted an in-depth review of the classification of hematolymphoid malignancies usin
SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced a peer-reviewed publication in Genome Research demonstrating that optical genome Mapping (OGM) can be an accurate, cost-effective method for detecting and sizing large repeat expansions, which are a class of structural variation (SV) linked to as many as 40 genetic disorders. Led by Alexander Hoischen and researchers at Radboud University Medical Center in the Netherlands, the study provides one of the most comprehensive evaluations to date of OGM as a single workflow for characterizing large repeat expansions. Researchers evaluated 85 subjects containing known pathogenic expansions in three
SAN DIEGO, April 08, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced a study published in The Journal of Molecular Diagnostics that describes a method for analysis of multiple myeloma (MM) by optical genome mapping (OGM). MM is one of the most common blood cancers, or hematologic malignancies, and is understood to be a difficult sample to analyze using traditional cytogenetics. Direct analysis of MM samples, by methods such as FISH or OGM, can be problematic because it is challenging to isolate enough cells with a known MM marker (CD138) on their surface, so-called CD138-positive cells. In this paper, researchers at Institute of Medical Genetics, Lille Univers
SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2024 and revenue outlook for 2025. "2024 has been an important year for Bionano. Despite a challenging external environment with shrinking capital budgets, financial uncertainty for our customers and difficult equity capital markets, we have continued serving our mission of transforming the way the world sees the genome and we believe we have identified a strategy to weather the storm. It is based on substantially lower operating expenses and a focus on the subset of optical genome mapping (OGM) and software customers
SAN DIEGO, and GREENWOOD, S.C., March 24, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) and Greenwood Genetic Center (GGC) today announced a publication in Genome Research describing the first study to use optical genome mapping (OGM) to investigate the genetic landscape of neural tube defects (NTDs). NTDs are the most common birth defect of the central nervous system and some of the most devastating congenital conditions. Despite an expected genetic link in as many as 60-70% of cases, methods currently in use, including karyotyping (KT), chromosomal microarray (CMA) and next-generation sequencing (NGS), collectively identify pathogenic gene variants in only about 8% of cas
SC 13G/A - Bionano Genomics, Inc. (0001411690) (Subject)
SC 13G/A - Bionano Genomics, Inc. (0001411690) (Subject)
SC 13G/A - Bionano Genomics, Inc. (0001411690) (Subject)
SC 13G - Bionano Genomics, Inc. (0001411690) (Subject)
SC 13G - Bionano Genomics, Inc. (0001411690) (Subject)